PMC4744075_01
Postoperative magnetic resonance imaging (MRI) in February 2011 . Left: Axial view. Right: Sagittal view
cureus-0008-000000000446-i01.jpg
PMC4744075_01_cureus-0008-000000000446-i01.jpg
FIG1
Her postoperative magnetic resonance imaging (MRI) is shown in Figure 1.
Magnetic resonance imaging (MRI) showing cerebellar vermis progression in November 2012. Left: Axial view. Right: Sagittal view
cureus-0008-000000000446-i02.jpg
PMC4744075_01_cureus-0008-000000000446-i02.jpg
FIG2
Seven months after ending the treatment, a cerebellar relapse in vermis was documented, requiring radiosurgery and temozolomide for four months, when a new progression in the same location was documented (Figure 2).
PMC4744075_02
In-111 DTPA octreotide scintigraphy in March 2013 showing moderate expression of somatostatin receptors. Left: 4 hours after infusion. Right: 24 hours after infusion
cureus-0008-000000000446-i03.jpg
PMC4744075_02_cureus-0008-000000000446-i03.jpg
FIG3
PMC4744075_03
Stable disease in magnetic resonance imaging (MRI) during octreotide treatment. Left (Top and Bottom): Axial and sagittal view in February 2014. Right (Top and Bottom): Axial and sagittal view in May 2015
cureus-0008-000000000446-i04.jpg
PMC4744075_03_cureus-0008-000000000446-i04.jpg
FIG4
By May 2015, she had undergone 24 months of treatment with a stable lesion on imaging (Figure 4) and clinical improvement, partially recovering independence and functionality, without any drug-related toxicity.